Below are the most recent publications written about "Myeloma Proteins" by people in Profiles.
-
Foureau D, Bhutani M, Guo F, Rigby K, Leonidas M, Tjaden E, Fox A, Atrash S, Paul B, Voorhees PM, Usmani SZ. Comparison of mass spectrometry and flow cytometry in measuring minimal residual disease in multiple myeloma. Cancer Med. 2021 10; 10(20):6933-6936.
-
Murray DL, Puig N, Kristinsson S, Usmani SZ, Dispenzieri A, Bianchi G, Kumar S, Chng WJ, Hajek R, Paiva B, Waage A, Rajkumar SV, Durie B. Mass spectrometry for the evaluation of monoclonal proteins in multiple myeloma and related disorders: an International Myeloma Working Group Mass Spectrometry Committee Report. Blood Cancer J. 2021 02 01; 11(2):24.
-
Gran C, Luong V, Bruchfeld JB, Liwing J, Afram G, Lund J, Usmani S, Alici E, Nahi H. Dynamic follow-up of smoldering multiple myeloma identifies a subset of patients at high risk of progression. Am J Hematol. 2021 03 01; 96(3):E63-E65.
-
Mateos MV, Kumar S, Dimopoulos MA, Gonz?lez-Calle V, Kastritis E, Hajek R, De Larrea CF, Morgan GJ, Merlini G, Goldschmidt H, Geraldes C, Gozzetti A, Kyriakou C, Garderet L, Hansson M, Zamagni E, Fantl D, Leleu X, Kim BS, Esteves G, Ludwig H, Usmani S, Min CK, Qi M, Ukropec J, Weiss BM, Rajkumar SV, Durie BGM, San-Miguel J. International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM). Blood Cancer J. 2020 10 16; 10(10):102.
-
Yan X, Xu XS, Weisel KC, Mateos MV, Sonneveld P, Dimopoulos MA, Usmani SZ, Bahlis NJ, Puchalski T, Ukropec J, Bellew K, Ming Q, Sun S, Zhou H. Early M-Protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma. Clin Transl Sci. 2020 11; 13(6):1345-1354.
-
Atrash S, Robinson M, Slaughter D, Aneralla A, Brown T, Robinson J, Ndiaye A, Sprouse C, Zhang Q, Symanowski JT, Friend R, Voorhees PM, Usmani SZ, Bhutani M. Evolving changes in M-protein and hemoglobin as predictors for progression of smoldering multiple myeloma. Blood Cancer J. 2018 11 08; 8(11):107.
-
Bhutani M, Landgren O, Usmani SZ. Multiple myeloma: is it time for biomarker-driven therapy? Am Soc Clin Oncol Educ Book. 2015; e493-503.